Physician profile
Chad E Tewell
NPI 1497046452
$1,167.72
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $732 · 2020: $17.44 · 2021: $89.36 · 2022: $90.12 · 2023: $111 · 2024: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $238.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $417.83 | 2021-2024 | Xacduro, Xerava |
| Merck Sharp & Dohme LLC | $157.07 | 2019 | |
| Viiv Healthcare Company | $118.66 | 2019 | |
| Janssen Biotech, INC. | $109.56 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $105.48 | 2019 | |
| Janssen Products, LP | $102.00 | 2019 | |
| Mayne Pharma Commercial LLC | $34.71 | 2019 | |
| Seqirus USA INC | $19.59 | 2019 | |
| Allergan, INC. | $17.44 | 2020 | |
| Theratechnologies INC. | $16.27 | 2019 | |
| Smith+Nephew, INC. | $15.26 | 2019 | |
| Insmed, INC. | $15.25 | 2019 | |
| Horizon Therapeutics Plc | $13.87 | 2019 | |
| Gilead Sciences, INC. | $13.28 | 2019 | |
| Mylan Institutional INC. | $11.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Tewell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.